What is Alflorex® ? – A probiotic supported by science

Alflorex® with the 35624® strain occurs naturally in the human gut. This unique strain has been clinically proven to reduce the symptoms of IBS.1

  • Bloating and Gas
  • Abdominal Pain
  • Diarrhoea and Constipation

Alflorex® is widely available throughout the UK and in over 22 countries around the world.


Try Alflorex® for Free

The Science behind the 35624® Strain

The 35624® strain was discovered and developed by scientists at Alimentary Health/ PrecisionBiotics, working in partnership with clinicians from one of the world’s leading centres of microbiome research, the APC Microbiome Ireland.

Download Resources
The Science of the 35624® Strain
Download About IBS
Download

Studies showed that the 35624® strain survives transit through the gut to reach the colon, its site of activity.2,3

The beneficial effects of Alflorex® are seen after 4 weeks and can take up to 2-3 months to take effect.1



Try Alflorex® for Free

The 35624® strain contained in Alflorex® is specifically mentioned in current BSG IBS treatment guidelines. Probiotics are also recommended in an increasing number of European guidelines4,5

BSG Guidelines
Download NICE Guidelines
Download

NICE recommends people with IBS who choose to try a probiotic, to take it for at least 4 weeks at the dose recommended by the manufacturer, while monitoring its effects6

NICE recommends healthcare professionals should consider assessment for IBS if the person reports having had any of the following symptoms for at least 6 months6

  • A Abdominal pain or discomfort
  • B Bloating
  • C Change in bowel habit [2008]

IBS Patient Impact

IBS affects approx. 12.6 million adults in the UK7*, and women are twice as likely to suffer than men6.

41% of women say they have IBS symptoms but have yet to be officially diagnosed (2019)8.

6 in 10 people in the UK regularly suffer from IBS (2018)9.

1 in 5 people in the UK have had to research public toilets before leaving the house10.

25% of people have cancelled plans last minute as a result of their gut symptoms IBS8.

Over 250,000 NHS employees suffer from IBS6.

Try Alflorex® for Free

References

  • Alflorex for IBS Patient Information Leaflet (PIL) rev.0 of 03/2018
  • Von Wright et al (2002) The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. International Dairy Journal 12:197-200.
  • Charbonneau et al (2013) Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 4:201-211.
  • Sabete J.M. and Jouet P. (2016) Prise en charge du Syndrome de l’Intestin Irritable (SII). SFNGE.
  • Pietrzak A., et al. (2018) Guidelines on the management of irritable bowel Syndrome. Gastroenterology Reviews 13: 259–288
  • National Institute for Health and Care Excellence (2008) Irritable bowel syndrome in adults: diagnosis and management. Clinical Guidelines 61; updated April 2017.
  • British Dietetic Association (BDA) (2013). Available at www.bda.uk.com/foodfacts/IBSfoodfacts.pdf. * Estimates based on BDA and Office for National Statistic
  • 8. Gut Health and Relationships survey 2019 (n=1,601), conducted by Healthista and sponsored by Alflorex March 2019
  • Gut Health Survey 2018 (n2,000), conducted by Atomik Research March 2018
  • Atomik Research (2018) on behalf of PrecisionBiotics Ltd. ‘Living with a sensitive gut’ (2,000 UK consumers)